Since 1996, NF research has been funded by Congress through Congressionally Directed Medical Research Programs (CDMRP) from the Department of Defense and through the National Institutes of Health (NIH).
Research that has been funded by Congress has resulted in the determination that the NF gene controls other pathways which are directly related to most forms of human cancer, cognitive disorders and heart disease affecting over 175 million Americans.
Clinical trials have begun to find medicines that will block these pathways.
Continued Congressional funding through the CDMRP and NIH is vital in funding pre-clinical and clinical trials and finding a treatment and cure for NF and its related disorders.
What we are seeking in Fiscal Year 2015
Defense Appropriations Request: $15 million for the Army’s Neurofibromatosis (NF) Research Program through the Army Research, Development, Test and Evaluation (RDT&E), Medical Advanced Technology account in the FY2015 Department of Defense Appropriations bill. (RDTE R-1 Line 30, PE # 0603002A)
Labor HHS Appropriations Request: Increased funding for Neurofibromatosis research at the National Institutes of Health (NIH). Specifically we are requesting that NF specific report language be included in the Office of the Director Account in the FY2015 Department of Health and Human Services, Education Appropriations bill.